US biotechs may withhold drugs from Italy
This article was originally published in Scrip
Executive Summary
Celgene and Biomarin would consider withholding new products from launch in Italy because of the hostile pricing environment there, and the impact on margins in other countries through reference pricing. BioMarin focuses on rare and orphan diseases, while Celgene specialises in oncology, haematology and inflammation/immunology. Both have a number of products in their late-stage pipeline.